Overexpression of PRDM16 attenuates acute kidney injury progression: genetic and pharmacological approaches

Abstract

Acute kidney injury (AKI) presents as a condition marked by a sudden and rapid decrease in kidney function over a short timeframe, resulting from diverse causes. As a transcription factor, PR domain-containing 16 (PRDM16), has recently been implicated in brown fat biogenesis and heart diseases. Our recent works indicated that PRDM16 could suppress the occurrence of renal interstitial fibrosis in diabetic kidney disorder. Nonetheless, the effect and regulatory mechanism of PRDM16 in AKI remain elusive. Our study demonstrated that PRDM16 inhibited apoptosis induced by ischemic/reperfusion (I/R) in BUMPT (Boston University mouse kidney proximal tubular) cells and HK-2(Human Kidney-2) cells. Mechanistically, PRDM16 not only bound to the promoter region of S100 Calcium Binding Protein A6 (S100A6)and upregulated its expression but also interacted with its amino acids 945–949, 957–960, and 981–984 to suppress the p38MAPK and JNK axes via inhibition of PKC-η activity and mitochondrial reactive oxygen species (ROS) production. Furthermore, cisplatin- and I/R-stimulated AKI progression were ameliorated in PRDM16 proximal-tubule-specific knockin mice, whereas exacerbated in PRDM16 knockout proximal-tubule-specific mice). Moreover, we observed that formononetin ameliorated I/R- and cisplatin-triggered AKI progression in mice. Taken together, these findings reveal a novel self-protective mechanism in AKI, whereby PRDM16 regulates the S100A6/PKC-η/ROS/p38MAPK and JNK pathways to inhibit AKI progression.

Keywords

AKI / apoptosis / PRDM16

References

[1] Ronco C, Bellomo R, Kellum JA. Acute kidney injury. Lancet (London, England). 2019; 394(10212): 1949-1964.

[2] Singbartl K, Kellum JA. AKI in the ICU: definition, epidemiology, risk stratification, and outcomes. Kidney Int. 2012; 81(9): 819-825.

[3] Ostermann M, Liu K. Pathophysiology of AKI. Best Pract Res Clin Anaesthesiol. 2017; 31(3): 305-314.

[4] Havasi A, Borkan SC. Apoptosis and acute kidney injury. Kidney Int. 2011; 80(1): 29-40.

[5] Priante G, Gianesello L, Ceol M, Del Prete D, Anglani F. Cell death in the kidney. Int J Mol Sci. 2019; 20(14): 3598.

[6] Linkermann A, Chen G, Dong G, Kunzendorf U, Krautwald S, Dong Z. Regulated cell death in AKI. J Am Soc Nephrol. 2014; 25(12): 2689-2701.

[7] Sury K, Perazella MA. The nephrotoxicity of new immunotherapies. Expert Rev Clin Pharmacol. 2019; 12(6): 513-521.

[8] Hess DC, Blauenfeldt RA, Andersen G, et al. Remote ischaemic conditioning-a new paradigm of self-protection in the brain. Nat Rev Neurol. 2015; 11(12): 698-710.

[9] Zhu L, Yuan Y, Yuan L, et al. Activation of TFEB-mediated autophagy by trehalose attenuates mitochondrial dysfunction in cisplatin-induced acute kidney injury. Theranostics. 2020; 10(13): 5829-5844.

[10] Xu ZH, Wang C, He YX, et al. Hypoxia-inducible factor protects against acute kidney injury via the Wnt/β-catenin signaling pathway. Am J Physiol Ren Physiol. 2022; 322(6): F611-F624.

[11] Liu S, Gao X, Wang Y, et al. Baicalein-loaded silk fibroin peptide nanofibers protect against cisplatin-induced acute kidney injury: fabrication, characterization and mechanism. Int J Pharm. 2022; 626: 122161.

[12] Iguchi M, Kakinuma Y, Kurabayashi A, et al. Acute inactivation of the VHL gene contributes to protective effects of ischemic preconditioning in the mouse kidney. Nephron Exp Nephrol. 2008; 110(3): e82-e90.

[13] Kim J, Park JW, Park KM. Increased superoxide formation induced by irradiation preconditioning triggers kidney resistance to ischemia-reperfusion injury in mice. Am J Physiol Ren Physiol. 2009; 296(5): F1202-F1211.

[14] Seale P, Bjork B, Yang W, et al. PRDM16 controls a brown fat/skeletal muscle switch. Nature. 2008; 454(7207): 961-967.

[15] Kundu A, Nam H, Shelar S, et al. PRDM16 suppresses HIF-targeted gene expression in kidney cancer. J Exp Med. 2020; 217(6): e20191005.

[16] Wang W, Ishibashi J, Trefely S, et al. A PRDM16-driven metabolic signal from adipocytes regulates precursor cell fate. Cell Metab. 2019; 30(1): 174-189. e5.

[17] Stine RR, Sakers AP, TeSlaa T, et al. PRDM16 maintains homeostasis of the intestinal epithelium by controlling region-specific metabolism. Cell Stem Cell. 2019; 25(6): 830-845. e8.

[18] Seale P, Kajimura S, Yang W, et al. Transcriptional control of brown fat determination by PRDM16. Cell Metab. 2007; 6(1): 38-54.

[19] Ohno H, Shinoda K, Spiegelman BM, Kajimura S. PPARγ agonists induce a white-to-brown fat conversion through stabilization of PRDM16 protein. Cell Metab. 2012; 15(3): 395-404.

[20] Chi J, Cohen P. The multifaceted roles of PRDM16: adipose biology and beyond. Trends Endocrinol Metab. 2016; 27(1): 11-23.

[21] Seale P, Conroe HM, Estall J, et al. Prdm16 determines the thermogenic program of subcutaneous white adipose tissue in mice. J Clin Invest. 2011; 121(1): 96-105.

[22] Kühnisch J, Theisen S, Dartsch J, et al. Prdm16 mutation determines sex-specific cardiac metabolism and identifies two novel cardiac metabolic regulators. Cardiovasc Res. 2024; 119(18): 2902-2916.

[23] Corrigan DJ, Luchsinger LL, Justino de Almeida M, Williams LJ, Strikoudis A, Snoeck HW. PRDM16 isoforms differentially regulate normal and leukemic hematopoiesis and inflammatory gene signature. J Clin Invest. 2018; 128(8): 3250-3264.

[24] Fei LR, Huang WJ, Wang Y, et al. PRDM16 functions as a suppressor of lung adenocarcinoma metastasis. J Exp Clin Cancer Res. 2019; 38(1): 35.

[25] Horn KH, Warner DR, Pisano M, Greene RM. PRDM16 expression in the developing mouse embryo. Acta Histochem. 2011; 113(2): 150-155.

[26] Xu F, Jiang H, Li X, et al. Discovery of PRDM16-Mediated TRPA1 induction as the mechanism for low tubulo-interstitial fibrosis in diabetic kidney disease. Adv Sci (Weinh). 2024; 11(7): e2306704.

[27] Cho YS, Challa S, Moquin D, et al. Phosphorylation-driven assembly of the RIP1-RIP3 complex regulates programmed necrosis and virus-induced inflammation. Cell. 2009; 137(6): 1112-1123.

[28] Das A, McDonald DG, Dixon-Mah YN, et al. RIP1 and RIP3 complex regulates radiation-induced programmed necrosis in glioblastoma. Tumour Biol. 2016; 37(6): 7525-7534.

[29] Mofid A, Newman NS, Lee PJ, et al. Cardiac overexpression of S100A6 attenuates cardiomyocyte apoptosis and reduces infarct size after myocardial ischemia-reperfusion. J Am Heart Assoc. 2017; 6(2): e004738.

[30] Iida S, Chen W, Nakadai T, Ohkuma Y, Roeder RG. PRDM16 enhances nuclear receptor-dependent transcription of the brown fat-specific Ucp1 gene through interactions with mediator subunit MED1. Genes Dev. 2015; 29(3): 308-321.

[31] Hu T, Wu Q, Yao Q, et al. PRDM16 exerts critical role in myocardial metabolism and energetics in type 2 diabetes induced cardiomyopathy. Metabolism. 2023; 146: 155658.

[32] Zhu S, Xu Y, Song M, et al. PRDM16 is associated with evasion of apoptosis by prostatic cancer cells according to RNA interference screening. Mol Med Rep. 2016; 14(4): 3357-3361.

[33] Wang T, Han S, Du G. S100A6 represses Calu-6 lung cancer cells growth via inhibiting cell proliferation, migration, invasion and enhancing apoptosis. Cell Biochem Funct. 2021; 39(6): 771-779.

[34] Li J, Wang T, Dang D. S100A6 could not promote the differentiation of Calu-6 lung cancer cell line. Ann Med Surg (Lond). 2024; 86(5): 2644-2650.

[35] Kumova OK, Galani IE, Rao A, et al. Severity of neonatal influenza infection is driven by type I interferon and oxidative stress. Mucosal Immunol. 2022; 15(6): 1309-1320.

[36] Aguilo F, Avagyan S, Labar A, et al. Prdm16 is a physiologic regulator of hematopoietic stem cells. Blood. 2011; 117(19): 5057-2066.

[37] Zhang XF, Ma JX, Wang YL, Ma XL. Calcyclin (S100A6) attenuates inflammatory response and mediates apoptosis of chondrocytes in osteoarthritis via the PI3K/AKT pathway. Orthop Surg. 2021; 13(3): 1094-1101.

[38] Tsoporis JN, Izhar S, Parker TG. Expression of S100A6 in cardiac myocytes limits apoptosis induced by tumor necrosis factor-alpha. J Biol Chem. 2008; 283(44): 30174-30183.

[39] Hao Y, Miao J, Liu W, Peng L, Chen Y, Zhong Q. Formononetin protects against cisplatin-induced acute kidney injury through activation of the PPARα/Nrf2/HO-1/NQO1 pathway. Int J Mol Med. 2021; 47(2): 511-522.

[40] Song XM, Yu Q, Dong X, et al. Aldose reductase inhibitors attenuate β-amyloid-induced TNF-α production in microlgia via ROS-PKC-mediated NF-κB and MAPK pathways. Int Immunopharmacol. 2017; 50: 30-37.

[41] Lee TH, Chen JL, Liu PS, Tsai MM, Wang SJ, Hsieh HL. Rottlerin, a natural polyphenol compound, inhibits upregulation of matrix metalloproteinase-9 and brain astrocytic migration by reducing PKC-δ-dependent ROS signal. J Neuroinflam. 2020; 17(1): 177.

[42] Sun J, Guo Y, Fan Y, Wang Q, Zhang Q, Lai D. Decreased expression of IDH1 by chronic unpredictable stress suppresses proliferation and accelerates senescence of granulosa cells through ROS activated MAPK signaling pathways. Free Radical Biol Med. 2021; 169: 122-136.

[43] Liu C, Hu F, Jiao G, et al. Dental pulp stem cell-derived exosomes suppress M1 macrophage polarization through the ROS-MAPK-NFκB P65 signaling pathway after spinal cord injury. J Nanobiotechnology. 2022; 20(1): 65.

[44] Chang SY, Sun RQ, Feng M, Li YX, Wang HL, Xu YM. BML-111 inhibits the inflammatory response and apoptosis of renal tissue in rats with hemorrhagic shock by inhibiting the MAPK pathway. Eur Rev Med Pharmacol Sci. 2018; 22(11): 3439-3447.

[45] Chen Y, Feng X, Hu X, et al. Dexmedetomidine ameliorates acute stress-induced kidney injury by attenuating oxidative stress and apoptosis through inhibition of the ROS/JNK signaling pathway. Oxid Med Cell Long. 2018; 2018: 4035310.

[46] Thongnuanjan P, Soodvilai S, Chatsudthipong V, Soodvilai S. Fenofibrate reduces cisplatin-induced apoptosis of renal proximal tubular cells via inhibition of JNK and p38 pathways. J Toxicol Sci. 2016; 41(3): 339-349.

[47] Cohen P, Levy JD, Zhang Y, et al. Ablation of PRDM16 and beige adipose causes metabolic dysfunction and a subcutaneous to visceral fat switch. Cell. 2014; 156(1-2): 304-316.

[48] Ivanochko D, Halabelian L, Henderson E, et al. Direct interaction between the PRDM3 and PRDM16 tumor suppressors and the NuRD chromatin remodeling complex. Nucleic Acids Res. 2019; 47(3): 1225-1238.

[49] Liao J, Jiang J, Jun H, et al. HDAC3-selective inhibition activates brown and beige fat through PRDM16. Endocrinology. 2018; 159(7): 2520-2527.

[50] Hu T, Morita K, Hill MC, et al. PRDM16s transforms megakaryocyte-erythroid progenitors into myeloid leukemia-initiating cells. Blood. 2019; 134(7): 614-625.

[51] Huang D, Wang C, Duan Y, et al. Targeting Oct2 and P53: formononetin prevents cisplatin-induced acute kidney injury. Toxicol Appl Pharmacol. 2017; 326: 15-24.

[52] Aladaileh SH, Hussein OE, Abukhalil MH, et al. Formononetin upregulates Nrf2/HO-1 signaling and prevents oxidative stress, inflammation, and kidney injury in methotrexate-induced rats. Antioxidants (Basel). 2019; 8(10): 430.

[53] Li X, Pan J, Li H, et al. DsbA-L mediated renal tubulointerstitial fibrosis in UUO mice. Nat Commun. 2020; 11(1): 4467.

[54] Li X, Pan J, Li H, et al. DsbA-L interacts with VDAC1 in mitochondrion-mediated tubular cell apoptosis and contributes to the progression of acute kidney disease. EBioMedicine. 2022; 76: 103859.

[55] Wang J, Pan J, Li H, et al. lncRNA ZEB1-AS1 was suppressed by p53 for renal fibrosis in diabetic nephropathy. Mol Ther Nucleic Acids. 2018; 12: 741-750.

[56] Chin SY, Pandey KN, Shi SJ, Kobori H, Moreno C, Navar LG. Increased activity and expression of Ca(2+)-dependent NOS in renal cortex of ANG II-infused hypertensive rats. Am J Physiol. 1999; 277(5): F797-804.

[57] Ai K, Pan J, Zhang P, et al. Methyl-CpG-binding domain protein 2 contributes to renal fibrosis through promoting polarized M1 macrophages. Cell Death Dis. 2022; 13(2): 125.

RIGHTS & PERMISSIONS

2024 The Author(s). MedComm published by Sichuan International Medical Exchange & Promotion Association (SCIMEA) and John Wiley & Sons Australia, Ltd.